BACKGROUND: Hyperhomocysteinemia may be a modifiable risk factor for the prevention of arteriosclerotic outcomes in patients with chronic kidney disease (CKD). Few clinical trials of homocysteine lowering have been conducted in persons with CKD before reaching end-stage renal disease. Kidney transplant recipients are considered individuals with CKD. OBJECTIVES: To describe the baseline characteristics of renal transplant recipients enrolled in a clinical trial of homocysteine lowering with astandard multivitamin containing high doses of folic acid and vitamins B(6) and B(12) aimed at reducing arteriosclerotic outcomes. Factors considered were level of kidney function, total homocysteine concentration, and prevalence of diabetes and previous cardiovascular disease (CVD). STUDY DESIGN: Cross-sectional survey within a randomized controlled trial cohort. SETTING & PARTICIPANTS: Participants were recruited from kidney transplant clinics in the United States, Canada, and Brazil. Eligible participants had increased levels of homocysteine (> or =12.0 micromol/L in men and > or =11.0 micromol/L in women) andkidney function measured by means of Cockroft-Gault estimated creatinine clearance of 30 mL/min or greater. RESULTS: Of 4,110 randomly assigned participants, 38.9% had diabetes and 19.5% had previous CVD. Mean total homocysteine concentration was 17.1 +/- 6.3 (SD) micromol/L, whereas mean creatinine clearance was 66.4 +/- 23.2 mL/min. Approximately 90% of the trial cohort had an estimated glomerular filtration rate consistent with stages 2 to 3 CKD (i.e., 30 to 89 mL/min). LIMITATIONS: Analysis is based on cross-sectional data from a randomized controlled trial, self-report of comorbid illnesses, and level of kidney function was estimated. CONCLUSIONS: A large population of stable renal transplant recipients who are at high risk of the development of CVD (both de novo and recurrent) has been recruited into the Folic Acid for Vascular Outcome Reduction in Transplantation Trial and are likely to experience a sufficient number of events to address the primary hypothesis of the trial.
RCT Entities:
BACKGROUND:Hyperhomocysteinemia may be a modifiable risk factor for the prevention of arteriosclerotic outcomes in patients with chronic kidney disease (CKD). Few clinical trials of homocysteine lowering have been conducted in persons with CKD before reaching end-stage renal disease. Kidney transplant recipients are considered individuals with CKD. OBJECTIVES: To describe the baseline characteristics of renal transplant recipients enrolled in a clinical trial of homocysteine lowering with a standard multivitamin containing high doses of folic acid and vitamins B(6) and B(12) aimed at reducing arteriosclerotic outcomes. Factors considered were level of kidney function, total homocysteine concentration, and prevalence of diabetes and previous cardiovascular disease (CVD). STUDY DESIGN: Cross-sectional survey within a randomized controlled trial cohort. SETTING & PARTICIPANTS: Participants were recruited from kidney transplant clinics in the United States, Canada, and Brazil. Eligible participants had increased levels of homocysteine (> or =12.0 micromol/L in men and > or =11.0 micromol/L in women) and kidney function measured by means of Cockroft-Gault estimated creatinine clearance of 30 mL/min or greater. RESULTS: Of 4,110 randomly assigned participants, 38.9% had diabetes and 19.5% had previous CVD. Mean total homocysteine concentration was 17.1 +/- 6.3 (SD) micromol/L, whereas mean creatinine clearance was 66.4 +/- 23.2 mL/min. Approximately 90% of the trial cohort had an estimated glomerular filtration rate consistent with stages 2 to 3 CKD (i.e., 30 to 89 mL/min). LIMITATIONS: Analysis is based on cross-sectional data from a randomized controlled trial, self-report of comorbid illnesses, and level of kidney function was estimated. CONCLUSIONS: A large population of stable renal transplant recipients who are at high risk of the development of CVD (both de novo and recurrent) has been recruited into the Folic Acid for Vascular Outcome Reduction in Transplantation Trial and are likely to experience a sufficient number of events to address the primary hypothesis of the trial.
Authors: Andrew S Levey; Kai-Uwe Eckardt; Yusuke Tsukamoto; Adeera Levin; Josef Coresh; Jerome Rossert; Dick De Zeeuw; Thomas H Hostetter; Norbert Lameire; Garabed Eknoyan Journal: Kidney Int Date: 2005-06 Impact factor: 10.612
Authors: A G Bostom; R Y Gohh; A J Beaulieu; M R Nadeau; A L Hume; P F Jacques; J Selhub; I H Rosenberg Journal: Ann Intern Med Date: 1997-12-15 Impact factor: 25.391
Authors: Michael G Shlipak; Linda F Fried; Mary Cushman; Teri A Manolio; Do Peterson; Catherine Stehman-Breen; Anthony Bleyer; Anne Newman; David Siscovick; Bruce Psaty Journal: JAMA Date: 2005-04-13 Impact factor: 56.272
Authors: A S Levey; J A Beto; B E Coronado; G Eknoyan; R N Foley; B L Kasiske; M J Klag; L U Mailloux; C L Manske; K B Meyer; P S Parfrey; M A Pfeffer; N K Wenger; P W Wilson; J T Wright Journal: Am J Kidney Dis Date: 1998-11 Impact factor: 8.860
Authors: Eva Lonn; Salim Yusuf; Malcolm J Arnold; Patrick Sheridan; Janice Pogue; Mary Micks; Matthew J McQueen; Jeffrey Probstfield; George Fodor; Claes Held; Jacques Genest Journal: N Engl J Med Date: 2006-03-12 Impact factor: 91.245
Authors: Sophia Zoungas; Barry P McGrath; Pauline Branley; Peter G Kerr; Christine Muske; Rory Wolfe; Robert C Atkins; Kathy Nicholls; Margaret Fraenkel; Brian G Hutchison; Robert Walker; John J McNeil Journal: J Am Coll Cardiol Date: 2006-02-23 Impact factor: 24.094
Authors: Myra A Carpenter; Matthew R Weir; Deborah B Adey; Andrew A House; Andrew G Bostom; John W Kusek Journal: Clin Transplant Date: 2012-07-09 Impact factor: 2.863
Authors: D E Weiner; M A Carpenter; A S Levey; A Ivanova; E H Cole; L Hunsicker; B L Kasiske; S J Kim; J W Kusek; A G Bostom Journal: Am J Transplant Date: 2012-05-17 Impact factor: 8.086
Authors: Petr Jarolim; Brian L Claggett; Michael J Conrad; Myra A Carpenter; Anastasia Ivanova; Andrew G Bostom; John W Kusek; Lawrence G Hunsicker; Paul F Jacques; Lisa Gravens-Mueller; Peter Finn; Scott D Solomon; Daniel E Weiner; Andrew S Levey; Marc A Pfeffer Journal: Transplantation Date: 2017-01 Impact factor: 4.939
Authors: Rakesh Malhotra; Ronit Katz; Daniel E Weiner; Andrew S Levey; Alfred K Cheung; Andrew G Bostom; Joachim H Ix Journal: Am J Hypertens Date: 2019-08-14 Impact factor: 2.689
Authors: Andrew G Bostom; Myra A Carpenter; John W Kusek; Andrew S Levey; Lawrence Hunsicker; Marc A Pfeffer; Jacob Selhub; Paul F Jacques; Edward Cole; Lisa Gravens-Mueller; Andrew A House; Clifton Kew; Joyce L McKenney; Alvaro Pacheco-Silva; Todd Pesavento; John Pirsch; Stephen Smith; Scott Solomon; Matthew Weir Journal: Circulation Date: 2011-04-11 Impact factor: 29.690
Authors: Aron M Troen; Tammy M Scott; Kristen E D'Anci; Denish Moorthy; Beverly Dobson; Gail Rogers; Daniel E Weiner; Andrew S Levey; Gerard E Dallal; Paul F Jacques; Jacob Selhub; Irwin H Rosenberg Journal: J Ren Nutr Date: 2011-12-06 Impact factor: 3.655
Authors: Daniel E Weiner; Meyeon Park; Hocine Tighiouart; Alin A Joseph; Myra A Carpenter; Nitender Goyal; Andrew A House; Chi-Yuan Hsu; Joachim H Ix; Paul F Jacques; Clifton E Kew; S Joseph Kim; John W Kusek; Todd E Pesavento; Marc A Pfeffer; Stephen R Smith; Matthew R Weir; Andrew S Levey; Andrew G Bostom Journal: Am J Kidney Dis Date: 2018-07-20 Impact factor: 8.860
Authors: Taimur Dad; Hocine Tighiouart; Alin Joseph; Andrew Bostom; Myra Carpenter; Lawrence Hunsicker; John W Kusek; Marc Pfeffer; Andrew S Levey; Daniel E Weiner Journal: Am J Kidney Dis Date: 2016-03-02 Impact factor: 8.860